Ayala Pharmaceuticals, Inc., a clinical-stage oncology company developing small molecule therapeutics for rare tumors and aggressive cancers, and Advaxis, Inc., a biotechnology company developing immunotherapies engineered using Listeria monocytogenes, have entered into a definitive merger agreement. The merger would result in a combined company that will focus predominantly on the development and commercialization of Ayala’s lead program AL102 for the treatment of desmoid tumors and Advaxis’s candidate ADXS-504 in development for prostate cancer.
